Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20751652 | 0.96 | MAPT (0.45) | MAPTRAB9AKMT2AALDH1A1GAA | |
| SCHEMBL17827653 | 0.90 | MAPT (0.48) | MAPTRAB9AKMT2AALDH1A1GAA | |
| SCHEMBL17827703 | 0.87 | MAPT (0.50) | MAPTRAB9AKMT2AALDH1A1GAA | |
| SCHEMBL17827657 | 0.86 | MAPT (0.42) | MAPTGAAHRH3DRD3KDM4E | |
| SCHEMBL17827658 | 0.82 | SLC2A1 (0.41) | MAPTRAB9AKMT2ACYP3A4HTT | |
| SCHEMBL20751685 | 0.81 | HTR2A (0.37) | MAPTKMT2AALDH1A1HRH3KDM4E | |
| SCHEMBL17827707 | 0.79 | CHKA (0.42) | MAPTRAB9AGAAHRH3NPC1 | |
| SCHEMBL17827663 | 0.77 | MAPT (0.55) | MAPTRAB9AKMT2AALDH1A1GAA | |
| SCHEMBL17827699 | 0.76 | MAPT (0.53) | MAPTRAB9AKMT2AALDH1A1GAA | |
| SCHEMBL16439227 | 0.75 | KMT2A (0.49) | MAPTRAB9AKMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027608-B1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-02-20 | — | — | EP | disclosed |
| US-20170291891-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-12 | — | — | US | disclosed |
| US-20170291891-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-12 | — | — | US | disclosed |
| US-20160168124-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-16 | — | — | US | disclosed |
| US-20160168124-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291891-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | MAVS, ZC3HAV1, PIR | MAPT 4504/4885RAB9A 898/4885KMT2A 2461/4885 |
| US-20160168124-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | MAVS, ZC3HAV1, PIR | MAPT 4504/4885RAB9A 898/4885KMT2A 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.